Turnstone Biologics CORP 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Turnstone Biologics Corp. has completed its merger with XOMA Royalty Corporation, becoming a wholly-owned subsidiary and delisting from Nasdaq.
Turnstone Biologics Corp. has formally executed separation and consulting agreements with its Chief Executive Officer and Chief Operating Officer, detailing severance packages and transitional consulting roles.
Turnstone Biologics Corp. has filed an amendment to its merger agreement with XOMA Royalty Corporation, primarily to include the full forms of the Contingent Value Rights Agreement and Tender and Support Agreement, detailing the $0.34 cash per share plus CVR offer.
8-K: Turnstone Biologics to be Acquired by XOMA Royalty in Cash and CVR Deal Amidst Operational Wind-Down
Turnstone Biologics Corp. has entered into a definitive merger agreement to be acquired by XOMA Royalty Corporation for $0.34 per share in cash plus one contingent value right, with the transaction expected to close in August 2025.
Turnstone Biologics announced its Q1 2025 financial results, highlighting a decrease in R&D expenses and net loss, while also revealing the exploration of strategic alternatives to maximize shareholder value.
Turnstone Biologics Corp. receives approval to transfer its listing to the Nasdaq Capital Market and gains an extension to meet minimum bid price requirements.
Turnstone Biologics announced its Q4 and full year 2024 financial results, discontinued its TIDAL-01 program, and initiated a strategic review to maximize shareholder value.
8-K: Turnstone Biologics Halts Clinical Studies, Explores Strategic Alternatives Amid Funding Concerns
Turnstone Biologics discontinues TIDAL-01 clinical trials and initiates a strategic review process, including potential sale or merger, due to capital-intensive requirements and challenging financial markets.
8-K: Turnstone Biologics Prioritizes Lead Program, Extends Cash Runway into 2026 After Restructuring
Turnstone Biologics announced a corporate restructuring to focus on its TIDAL-01 program, extending its cash runway into the second quarter of 2026.
Turnstone Biologics is prioritizing its pipeline, reducing its workforce by approximately 60%, and making leadership changes to focus on its Phase 1 program and extend its cash runway into the second quarter of 2026.
Turnstone Biologics Corp. received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing its listing at risk.
8-K: Turnstone Biologics Announces Positive Phase 1 Trial Results and Second Quarter 2024 Financials
Turnstone Biologics reported positive initial data from its Phase 1 trial of TIDAL-01 in metastatic colorectal cancer, including a complete response in one patient, and announced its second quarter 2024 financial results.
Turnstone Biologics Corp. held its annual meeting on June 3, 2024, where stockholders voted on the election of directors and the ratification of the company's independent auditor.
Turnstone Biologics announced its first quarter 2024 financial results, highlighting progress in its Selected TIL therapy development and securing a $20 million credit facility.
Turnstone Biologics Corp. reports the resignation of Patrick Machado from the Board of Directors and the appointment of William Waddill as a new director, effective April 15, 2024.
Turnstone Biologics announced its fourth quarter and full year 2023 financial results, highlighting the advancement of its lead program, TIDAL-01, and other business developments.
Turnstone Biologics is pioneering next-generation Selected TIL therapy, with initial clinical data from Phase 1 trials expected in mid-2024, targeting a range of solid tumors including colorectal, head and neck, and breast cancers.